中国组织工程研究与临床康复第13卷第5期2009–01–29出版JournalofClinicalRehabilitativeTissueEngineeringResearchJanuary29,2009Vol.13,No.5ISSN1673-8225CN21-1539/RCODEN:ZLKHAH9971DepartmentofCardiothoracicSurgery,FirstAffiliatedHospitalofNanchangUniversity,Nanchang330006,JiangxiProvince,China;2DepartmentofCardiothoracicSurgery,SecondAffiliatedHospitalofNanchangUniversity,Nanchang3300006,JiangxiProvince,ChinaLiuJi-chun☆,Doctor,Professor,Chiefphysician,DepartmentofCardiothoracicSurgery,FirstAffiliatedHospitalofNanchangUniversity,Nanchang330006,JiangxiProvince,Chinaliujichun999@yahoo.com.cnSupportedby:KeyProgramofMinistryofPublicHealthofJiangxiProvince,No.20020206*Received:2008-06-17Accepted:2008-07-22(54200806170008/G)LiuJC,XuJJ,WanYH,RaoHG,WangQ,LiZP,LiuS,WuQC,GaoT,ChenG.Orthotopichearttransplantationin3cases.ZhongguoZuzhiGongchengYanjiuyuLinchuangKangfu2009;13(5):997-1000(China)[http://www.crter.cnhttp://en.zglckf.com]Orthotopichearttransplantationin3cases*☆LiuJi-chun1,XuJian-jun2,WanYu-hua1,RaoHua-geng1,WangQin1,LiZhi-ping1,LiuSheng1,WuQi-cai1,GaoTao1,ChenGan1Abstract:ThreecasesofterminalstageheartdiseasereceivedorthotopichearttransplantationattheDepartmentofCardiothoracicSurgery,theFirstHospitalofNanchangUniversitybetweenAugust2001andDecember2003.Thesethreecaseswereallfemaleanddiedofbraindeath.Bodyweightdifferencebetweendonorandrecipientwaslessthan20%.AllthreecasesunderwentsuperiorandinferiorvenacaveosculationandreceivedimmunosuppressivetherapyofcyclosporineA,prednisone,andmycophenolatepostoperatively.Theyweresuccessfullydiscarded.HeartfunctionrecoveredtogradeI-II(NYHA).Noinfectionorseriousrejectionwasfoundduringthesurgery.Theseresultsindicatethatgooddonorheartpreservation,consummateperioperativeprocessing,andproperimmunosuppressivetherapyarethekeymeasuresofsuccessfulhearttransplantation.INTRODUCTIONHearttransplantationisoneofthemosteffectivemethodstotreatend-stageheartdisease.Thepresentstudyretrospectivelyanalyzed3caseswhohadsuccessfullyreceivedorthotopichearttransplantationduetoend-stageheartdiseaseattheDepartmentofCardiothoracicSurgery,FirstAffiliatedHospitalofNanchangUniversitybetweenAugust2001andDecember2003.SUBJECTSANDMETHODSCasedataCase1wasa20-year-oldmalepatientwhosufferedfromhypertrophiccardiomyopathy.Hecomplainedoftachypneaandchestdistressafteractivityfor7yearsandedemaoflowerlimbsfor4years,andreceivedimplantationofheartpacemaker3yearsago.Physicalexaminationresultsrevealedblood-pressure110/73mmHg(1mmHg=0.133kPa)andbodyweight50kg.Physicalsignsshowedchronicdiseaseface,withoutjugularvaricosityandandauscultationresultsrevealedclearrespiratorysoundwithoutcracklesintwolungs,apicalbeatdispersion,feelingoffavorinprecordium,therealmofheartamphi-expanding,heartrate60beatsperminutewithregularcardiacrhythm,withoutTraube'smurmur,andgradeⅡsystolicmurmurinapicalregion.Inaddition,positivesignofascitesandpittingedemainbothlowerextremitieswerealsofound.Electrocardiogramshowedsinusrhythmandsupervoltageinleftventricle.Ultrasoniccardiographyshowedpachynsisinbothventricles,leftventricularend-diastolicdimension76mm,andejectionfraction0.38.Mecicinwasusedtoimproveheartfunctionbeforeoperation.Case2wasa49-year-oldfemalepatientwhosufferedfromdilatedcardiomyopathy.Hecomplainedoftachypneaandcardiopalmusrepeatedlyfor5years,edemaoflowerlimbsfor4years,anddiabetesfor3years.Physicalexaminationresultsrevealedbloodpressure80/50mmHgandbodyweight53kg.Herphysicalsignsshowedchronicdiseaseface,sit-upposition,puffinessofeyelidandface,slightcyanosisoforallip,andauscultationresultsrevealedcoarserespiratorysoundwithoutcracklesintwolungs,apicalbeatdispersion,therealmofheartexpandtobottomleft,heartrate60beatsperminutewitharrhythmia,auscultationofheartshowingbearingprematurewithgalloprhythm,andgradeⅢsystolicmurmurinapicalregion.Liverwaspalpated3centimetersbelowribs,pittingedemainbothlowerextremities.Electrocardiogramshowedsinusrhythm,degreeⅠauriculoventricularblock,abiogenesisofventricularprematurecontraction.Ultrasoniccardiographyshowedbackstreamingofmitralvalveandtricuspidvalve,leftventricularend-diastolicdimension72mm,andejectionfraction0.38.Bloodsugarwas3.3mmol/Lbeforemealand10.9mmol/Ltwohoursaftermeal.DiabeticdietandMecicinwereusedtoimproveheartfunctionpreoperatively.Case3wasa57-year-oldmalepatientwhosufferedfromterminal-stagecoronaryarterydisease.Hecomplainedoftachypneaandcardiopalmusafterexercisefor10yearsandhadreceivedmedicinetreatmentfor5yearsapproximately,butthediseasewasmoreseverethereafter.Physicalexaminationresultsrevealedthatbloodpressure90/55mmHgandbodyweight76kg.Hisphysicalsignsshowedchronicdiseasefaceandauscultationresultsrevealedcoarserespiratorysoundandfinecracklesintwolungs,apicalbeatdispersion,therealmofheartexpandtobottomleft,heartrate76beatsperminutewithregularcardiacrhythm.AuscultationresultsrevealedgradeⅡsystolicmurmurinapicalregion.Liverwaspalpated3centimetersbelowribs,pittingedemainbothlowerextremities.Electrocardiogramshowedsinusrhythm,degreeⅠauriculoventricularblock,andobsoleteanteriormyocardialinfarction.Inaddition,vntricularaneurysmwascuedbythechangeofST-T.Ultrasoniccardiographyshowedthatatriumsinistrumandleftventricleenlargedapparently,theanteriorwallofleftventriclebecamethin,echoenhancementandflatmobilityappear,thewallofApexofheartbecamethinandinflatedoutside,presentingparadoxicalmotion,leftventricularend-diastolicdimensionwas70mm,andejectionfractionwas0.35.CoronaryarteriongraphyClinicalMedicineLiuJC,etal.Orthotopichearttransplantationin3casesP.O.Box1200,Shenyang110004cn.zglckf.com998www.CRTER.orgshoweddiffusedstegnosisandleftvntricularaneurysm.Mecicinwasusedtoimproveheartfunctionpreoperatively.DonorinformationAll3donorswereyoungmale,sufferingfrombraindeath.Theyhadgoodhealthandnohistoryofangiocardiopathy.TheirABObloodtypeswereidenticalwiththerecipients.Theratiooflymphocytoxicantibodytestwaslessthan10%.Cytomegalovirus,EBvirus,hepatitisvirusandHIVintheserumwerenegative.Bodyweightdifferencebetweendonorsandrecipientswaslessthan20%.MethodsPriortoremovalofdonorheart,1000-1200mLof4℃modifiedSt.Thomasliquidwasinfusedintoaorticroot.Meanwhile,icewasputintothepericardialcavitytokeephypothermy.Aftertakenout,theheartwasinfusedwith4℃UWliquidthroughtheaorticrootandpreservedinanicedbox.Enoughlengthofsuperiorandinferiorvenacaveshouldbereserved.Amedianincisionwasmadeonthesternumtoexposetheheart.Extracorporealcirculationwasestablishedbyintubationatthesuperiorandinferiorvenacaveandascendingaortaaftergeneralheparinization.Intubationshouldbeperformedremotely.Theatriunmsinistrumdrainagetubewasplacedintotherightsuperiorpulmonaryveinandusedfordrippingoficedphysiologicalsalineduringinosculationandforatriumsinistrumdrainageafterinosculation.Theintervalsbetweenaortaandpulmonaryarteryneedtobedissociatedaswell.Afteraortalblockage,heartwasexcisedalongtheauriculoventriculargrooveandsemilunarvalveswithposteriorwallofleftatriumpreserved.Followingtrimmingofthedonorheart,atriumsinistrumwasover-and-oversuturedwith4/0prolenethread.Onestitchstartedfromtherootofsuperiorleftpulmonaryveinuntilatrialseptum,andthentheotherstitchwassuturedtoartialseptumcontinuouslyandknottedwiththefirststitch.Theinferiorvenawassuturedusing4/0prolenethread.Thelocationofdonorheartwasfixed,andthedebouchementofaortalandpulmonaryarterywasproperlytrimmed.Pulmonaryarterywassuturedfrommidpointofposteriorwallfirstly.Theanteriorwallofpulmonaryarterywasnotsutureduntilaortalopening.Subsequently,theaortawassuturedstartingfromtheposteriorwall.Aortalclampwasremovedafteraortalventing.Atriumsinistrumdrainagewasperformedatthesametime,followedbyintravenousinjectionof500mgmethylprednisolone.Thereafter,theanteriorwallofpulmonaryarteryandsubsequentsuperiorvenacavaweresutured.Followingheartrecovery,hemorrhagewascarefullyexamined.Extracorporealcirculationwasceasedwhenpowerfulheartbeatwasfelt.Epicardialpacingwirewaspositionedroutinely.Pericardiumwasinterruptedlysutured.Drainageofthemediastinumandpericardiumwereperformed,followedbylayer-by-layerclosure.Aftersurgery,patientswereaskedtostayintheIntensiveCareUnit.Electrocardiogram,arterialpressure,O2saturation,electrolyteandarterialbloodgasanalysisweremonitored.Breathingmachinewasusedtoassistventilation.Cephalosporin-Ⅲwasusedforoneweek,andmedicinewasusedtostrengthheart,diuresisandbloodvesselexpansion.Meprednisone(500mg)wasusedintheprocessofopeningaortalclamp.Ciclosporin-A,prednisone,andmycophenolatewereappliedtoresistrejection.CiclosporinAdosewasregulatedaccordingtoitsserumconcentration,maintainingat200-300μg/L.Prednisonewasadministeredat1mg/kgforoneweekandthenitsdosewasgraduallydecreased.Mycophenolatewasorallytaken500mgonce,3timesperday.Incase2,insulinwasusedtocontrolbloodglucoseimmediatelyafterbeginningofpost-surgery.Acarboseanddiamicronwereusedtoinsteadofinsulinwhenthepatientbegantoeat.Bloodglucoseconcentrationwasstrictlymonitoredatthesametime.MainoutcomemeasuresEvidencesofacuterejectionSymptomsandsigns,electrocardiogram(ECG),ultrasoniccardiography(UCG),cyto-detection,andserologicalindices.MainsymptomsAcratia,low-gradefever,lassitude,cardiopalmus,dyspnoea,andanepithymia.MainmonitorsofinfectionX-rayfilmsofchest,viralantibodyinserum,cultivationsofsputum,urine,stercus,andeumycete.RESULTSFollow-upresultsSeriousbleeding,malignantarrhythmia,andrightheartfailurewerenotfoundinall3patients.Noseriousinfectionorrejectionoccurredduringthesurgery.HeartfunctionhadimprovedobviouslyandrecoveredtogradeI-IIonemonthaftersurgery.Case1exhibitedepilepticseizure2daysaftersurgery,whichdisappearedafterthiopentoneandcarbamazepinetreatment.Allof3patientsweresuccessfullydischarged.Case1diedofmalignantarrhythmia8monthsaftersurgery,case2diedofseriouspulmonaryinfection6monthsaftersurgery,andcase3wasfollowedupfor27monthsandfoundsurviving.Generalconditionandfollow-upresultsof3patientswhounderwentorthotopichearttransplantationareshowninTable1.Table1Baselinematerialandfollow-upresultsCaseGenderAge(yr)EtiologyDonorTherapyComplicationFollow-upResults1Male20HypertrophiccardiomyopathyBraindeathOrthotopicbicavalhearttransplantationNoneDiedofmalignantarrhythmiacordis8monthsaftersur-gery2Female49DilatedcardiomyopathyBraindeathOrthotopicbicavalhearttransplantationNoneDiedofseverelunginfec-tion6monthsaftersur-gery3Male57Terminal-stagecoronaryarterydiseaseBraindeathOrthotopicbicavalhearttransplantationNoneSurvivingLiuJC,etal.Orthotopichearttransplantationin3casesISSN1673-8225CN21-1539/RCODEN:ZLKHAH999www.CRTER.orgDISCUSSIONChoiceofdonorandrecipientSuitablerecipientisoneofthemajorfactorsforasuccessfultransplantation.UNOShadenacteddetailedcriteriaforselectingrecipient[1]:Patientswhosufferedfromterminalstageheartdiseases,suchasprimarycardiomyopathy,diffusedischemicheartdisease,congenitalheartdiseasewhichcannotbecured;theexpectedsurvivaltimewasnomorethan6-12months,agewasunder55years,pulmonaryvascularresistancewasbelow6woodunits,withoutseverestructuraldiseaseinotherorgans.Theevidencesforchoosingdonorswereasfollows:theimmuno-compatibilitybetweendonorandrecipientshouldbeidentical,includingtheABObloodtypeandlymphocytoxicantibodytestbenegative;thedifferencesofheartsizeandbodyweightbetweendonorandrecipientshouldbenomorethan20%.Inthepresentstudy,all3caseswerethepatientswhosufferedfromterminalstageheartdisease,anddifferenceofbodyweightbetweendonorandrecipientwas+9%,+15%,and-8%,separately.Protectionofdonor’sheartItisimportanttoprotectthedonor’sheartfavorableforasuccessfultransplantation.Itisconsideredsignificanttoshortenthewarmischemiaandcoldischemiatimeofheart.However,theischemiatimeofheartiscloselycorrelatedtotheconditionsofdonor’sheart,andoperator’spreparationandproficiency[2-3].Thespecificmeasureswetookwereasfollows:①Stablishingartificialrespirationassoonasdonorsufferingfrombraindeath,maintainingastablehemodynamicsasfaraspossible.②Infusingcoldhypso-kaliumliquidintotheaortalroottostopthedonorheartbeatingindiastolicphase.③Shorteningthetimefordonorhearttransportationandsuturingthedonorheartassoonaspossible.④Performingsomeanimaltestsandmodelexperimentspreoperativelytoimproveoperator’sproficiency.Thewarmischemiatimeofthreepatientswas3,5,and6minutes,separately,andcoldischemiatimewas165,190,and180minutes,separately,gainingafavorableeffectofmyocardialpreservation.It’scriticaltoshortenthewarmischemiatimeforgettingahighqualityofdonorheart.TransplantationstyleTherearethreemethodsofinosculation:standardtechnique,bicavalanastomotictechnique,andtotalorthotopichearttransplantation.Thefirsttwomethodsarefrequentlyused.Wangetal[4]thoughtthatbicavalanastomotictechniqueonlyleftonesinusnode,avoidingcardiacarrhythmiaanddisorderofhaemodynamicscausedbybackflowofatrioventricularvalve;bicavalanastomotictechniquewasalsomucheasierthantotalorthotopichearttransplantation,decreasingtheprobabilityofstomalbloodleakage.Inthepresentstudy,bicavalanastomotictechniquewasemployedinall3patients.Resultsrevealedthatseriouscardiacarrhythmiasdidnotoccurpostoperatively,andthebackflowoftricuspidwasslight.ImmunosuppressivetherapyandrejectionmonitoringCiclosporin,prednisoneandmycophenolatewereadoptedintheimmunosuppressivetherapy.Seriousrejection,leucocytopenia,ormyelosuppressiondidnotoccur.Attheearlyperiodfollowingsurgery,valleyvalueofciclosporinAdecreasesslightly,andciclosporinAdoseisregulatedaccordingtoitsserumconcentration,maintainingat200-300μg/L.Attheinitialstagefollowingsurgery,itisbettertomaintainthevalleyvalueofciclosporinatarelativelyhighstandard,regulatingittothenormallevelgraduallytwomonthslater.Electrocardiogram,ultrasoniccardiography,cyto-detection,X-rayfilmsandserologicalindices,aswellasclinicalsymptomsandsignswereusedtomonitorrejection.Althoughmyocardialbiopsyisthoughttobethegoldstandardofacuterejection[5],twocasesdidnotundergoitinthisstudy.Becausemyocardialbiopsyisaninvasiveandexpensiveprocedureandcancausementalstresstothepatients,it’sbetternotdoitrepeatedly.Myocardialbiopsyisselectedwhenthepresenceofrejectionissuspected.PreventionofinfectionInfectionisthesecondmajorfactorcausingdeathattheearlystagefollowinghearttransplantationandisthemostcommonfactorcausingdeathattheadvancedstage.Infectionfrequentlyoccursattheearlystageofhearttransplantation,inparticularinthefirstfewweeks[6].Inthepresentstudy,severeinfectiondidnotoccurinall3patientsbecausesomeprotectivemeasureswereused,includingstrictsterilizationandinsulation,chestX-raymonitoring,cultivationofbacteriumandeumycete,pullingoutvariouskindsofinvasivetubes,trachealintubation,applicationofbroad-spectrumantibioticandantiviraldrug,andencouragedoingactivitiesinpatients.PreventionandmanagementofbleedingHearttransplantationmajorsinsuturingvessels.Itisgreatlyimportanttopreventbleeding.Firstly,weneedtotrimthetissuefromdonorandrecipienttobematched.Secondly,thedistancebetweeneverytowpinsneedstobewell-distributed,especiallyforthebackofheart.Thirdly,enoughplateletshouldbepreparedpriortosurgery.Fourthly,somemethodsshouldbeappliedtostopbleedingduringthesurgery.REFERENCES[1]FleischerKJ,BaumgartnerWA.Hearttransplantation.In:EdmundsHL.Cardiacsurgeryintheadult.NewYork:McGraw-Hill.1997:1409-1449.[2]MullenJC,BentleyF,MordyDL,etal.Extendeddonorischemictimesandrecipientoutcomeafterorthotopiccardiactransplantation.CanJCardiol.2001;17(4):421-426.[3]LiuS,HuangL.Experimentalresearchofdonator’swarmischemiatimelimit.JiangxiYixueyuanXuebao.1999;39(4):95-96.[4]WangCS,ChenH,HongT,etal.Clinicstudyof56successfulorthotopichearttransplantations.ZhonghuaYixueZazhi.2004;84(19):1589-1591.[5]ZhaoTB,GuanZZ,WangP,etal.Clinicutilizationofmyocardialbiopsyafterhearttransplantation.ZhonghuaQiguanYizhiZazhi.1997;18(1):31-33.[6]MontoyaJG,GiraldoLF,EfronB,etal.Infectiouscomplicationsamong620consecutivehearttransplantpatientsatStanfordUniversityMedicalCenter.ClinInfectDis.2001;33(5):629-640.LiuJC,etal.Orthotopichearttransplantationin3casesP.O.Box1200,Shenyang110004cn.zglckf.com1000www.CRTER.org原位心脏移植3例*☆刘季春1，徐建军2，万于华1，饶华庚1，王勤1，李志平1，刘升1，吴起才1，高涛1，陈干1(1南昌大学第一附属医院心胸外科，江西省南昌市330006；2南昌大学第二附属医院心胸外科，江西省南昌市330006)刘季春☆，男，1960年生，江西省贵溪市人，汉族，2004年南昌大学医学院毕业，博士，教授，主任医师，主要从事心脏病外科治疗的相关研究。江西省卫生厅重点招标资助项目（20020206）*摘要：2001-08/2003-12南昌大学第一附属医院心胸外科分别为3例终末期心脏病患者进行了原位心脏移植，3例供者均为青年男性脑死亡者，供者与受者体质量差异均小于20%。3例受者均采用双腔静脉吻合法，移植后采用环孢素A、强的松及霉酚酸酯联合免疫抑制治疗。3例患者均顺利出院，心功能恢复至NYHAⅠ~Ⅱ级，围手术期无感染或严重排斥反应发生。提示良好的心肌保护、完善的围手术期处理以及合理的抗排斥治疗是心脏移植成功的关键。关键词：心脏移植；免疫抑制；心肌保护；器官移植中图分类号:R617文献标识码:A文章编号:1673-8225(2009)05-00997-04刘季春，徐建军，万于华，饶华庚，王勤，李志平，刘升，吴起才，高涛，陈干.原位心脏移植3例[J].中国组织工程研究与临床康复，2009，13(5):997-1000[http://www.crter.orghttp://cn.zglckf.com](EditedbyHeiFL/SongLP/WangL)文题：以准确和特征为重点，可以采用主副标题的形式。背景：应突出与目的、结论有一致性的呼应关系。目的：具有创新性结果的文章，以假设为描述用语时，一般不要说对XXX机制的研究，因为许多实验并非真正去研究机制，而只是对作用途径、作用过程的再验证。以验证为目的的实验，文章应重点描述结果中有特殊意义的内容，切忌应用泛泛的概括性语言。验证的结果可以是阳性的，也可以是阴性的，阴性的结果可能更有意义。设计、时间及地点：可以科研设计类型、统计学方法类型、实验方法学水平详细和准确的去描述，地点为实验完成的单位。结论：重在描述本文结果的创新性意义，本文结果区别与他篇的不同之处。引言：描述本文课题的起源、发展过程，以及本文发表的意义，文字可相当于讨论的1/2或1/3。材料/对象(参与者)和方法：这是文章描述的重点，应突出可重复性的原则。对象：参与者要有自愿原则，知情原则，伦理委员会通过原则，应用符合国际或国内的相关法律或条例，以参考文献注明。参与者：应有纳入条件，排除条件，分组条件，基线分析。实验动物：也有伦理原则，应用符合国际或国内的相关法律或条例，以参考文献注明。相关治疗医生资质：患者的治疗可以是同一个医生，也可以是一个治疗组的几名医生，要有医生及医生组的资质水平描述，应用符合国际或国内的相关法规或条例，以参考文献注明。材料：描述动物、仪器、试剂、设备、药物、产品，来源，型号，厂家，国家，批号、含量、作用、用途等，要有名称、量，厂家，产地等。除实验动物外，其他用表描述。方法/干预：分自然段的描述用语：实验过程、实验方法、实验造模、实验干预、技术路线、置入过程、移植过程、修复治疗过程等。实验过程：较复杂的分组、实验程序应以实验流程表显示。对实验动物造模，组织学、病理学、免疫组化学、影像学、行为学检测步骤应具体描述。一般以客观标准在前，主观标准在后。实验干预：人为施加的各种因素。中药应描述制剂类型、服药方法(水煎剂，粉剂，化学淬取，含药血清，灌胃，腹腔注射，局部外敷等)与效果及偏倚和不足的关系。针灸应描述部位、针具、时间、深度、强度、频率等与效果及偏倚和不足的关系。技术路线:置入过程:移植过程：修复治疗过程：主要观察指标：包括评价方法，评价指标，评价结果。随访情况：应是具体时间。设计、实施、评估者：统计学分析：具体方法，统计者。结果：合理使用图表，彩图，图表要体现出足够的自明性。数量分析：参与者/动物，脱落原因，脱落率。基线资料：效果分析：统计描述；统计推断。随访情况：时间要准确，对应到每一个或每一组的参与者。不良反应：组织工程研究主要的问题表现在生物相容性方面。可能影响结果的因素：组织工程研究中主要影响生物相容性的表现是材料、宿主、技术操作3者之间的多种影响因素。结果描述的顺序：由重点、次重点到非重点。一般为客观结果（金标准，重复时无差异）在前，主观结果（重复时可有差异）在后。从组织学、病理学、免疫组化学、影像学、行为学检查等结果的角度和顺序描述。以表说明时不应再重复同样的文字。多利用三线表、直方图、条图、饼型图，更直观的说明结果。以细胞图显示时应有箭头指示。应有对偏倚及不足的描述。讨论：不要太多运用他人的理论内容，会影响和冲淡文章结果的分量。描述文章结果中具有创新性意义的一两个观点，说明文章内容与他人他篇的异同点。对假设的结果验证为阳性或是阴性时的合理解释。对偏倚及不足的客观描述，对应用前景的简单描述。结论：对文章结果的定性和/或定量的描述。文章辅文：课题背景：描述文章的内容与基金资助宗旨的关系及意义，基金资助项目名称、项目号，文章反映了基金项目课题设计中哪些方面的成果，体现本文的重要意义。作者介绍：作者中的院士、博导、国际专家、学科知名专家、学科首席专家在这一研究领域的地位，以及对此课题和对本文章的贡献，体现本文的可信性。重点实验室：实验完成的单位，如为国家及省部委重点实验室，应介绍本实验室以往完成的实验对本领域的贡献，以及实验室级别和仪器设备水平适应本领域研究的地位，体现文章实验过程的严谨性、科学性。同行评价：对文章特点简要科学的评价。偏倚或不足：说明本文作者严肃的科学态度。注意：文章中尽量少用括号，以语言修饰能力解决语气感，以利于连续阅读。文章中使用缩略语应在3个以内，以减少阅读障碍。CRTER杂志对研究原著稿件修改的语言描述要求ISSN1673-8225CN21-1539/R2009年版权归《中国组织工程研究与临床康复》杂志社所有
